Therapy News and Research

RSS

R. Bryan Miller Symposium to spotlight special focus on rare disease research

The University of California, Davis Department of Chemistry will spotlight a special focus on rare disease research with this year's 15th annual R. Bryan Miller Symposium. Experts in rare diseases will gather at the UC Davis Conference Center March 5 for a conference highlighting the opportunities and challenges in applying cutting edge technologies and "precision medicine" to better treat conditions that together affect millions of people, especially children.

16 Feb 2015

Novartis receives priority review status from FDA for heart failure medicine LCZ696

Novartis announced today that the US Food and Drug Administration has granted priority review for LCZ696, an investigational medicine for the treatment of heart failure with reduced ejection fraction (HFrEF). The designation is intended to accelerate the review of therapies that offer a significant improvement in the safety or effectiveness of the treatment, prevention or diagnosis of a serious condition.

16 Feb 2015

Researchers identify two cell-signaling molecules that appear critical to stalling cancer's spread

In what is believed to be the largest epigenetic analysis to date of cell-signaling molecules in early-stage melanoma, researchers at NYU Langone Medical Center and its Laura and Isaac Perlmutter Cancer Center have identified two tiny bits of non-coding genetic material in primary tumors that appear critical to stalling the cancer's spread -- and essentially setting the biological fate of the disease.

15 Feb 2015

Pelvalon receives FDA approval to market Eclipse System for improving bowel control in women

Pelvalon announced today that the U.S. Food and Drug Administration has granted the company's de novo request to market the Eclipse System, the first vaginal insert designed to provide bowel control, in the United States. Loss of bowel control, also known as fecal incontinence, is a condition that affects over 20 million women in the U.S.

14 Feb 2015

$Eisai announces FDA approval of LENVIMA (lenvatinib) for treatment of RAI-refractory DTC$

Eisai announces FDA approval of LENVIMA (lenvatinib) for treatment of RAI-refractory DTC

Eisai Inc. announced today that the U.S. Food and Drug Administration approved the company's receptor tyrosine kinase inhibitor LENVIMA (lenvatinib) for the treatment of locally recurrent or metastatic, progressive, radioactive iodine-refractory differentiated thyroid cancer (RAI-R DTC).

13 Feb 2015

PAH survival unaffected by rheumatoid arthritis origin

Patients with rheumatoid arthritis-associated pulmonary arterial hypertension have comparable survival to those with idiopathic pulmonary arterial hypertension, researchers report.

13 Feb 2015

Radionuclide angiography-assessed RVEF predicts PAH outcomes

Baseline right ventricular ejection fraction as evaluated by conventional planar equilibrium radionuclide angiography is significantly associated with outcomes in patients with pulmonary arterial hypertension, research suggests.

13 Feb 2015

Retinal venular calibre predicts ranibizumab vision improvement

Retinal venular calibre may predict visual outcome in diabetic macular oedema patients given the anti-vascular endothelial growth factor monoclonal antibody ranibizumab, a pilot study suggests.

13 Feb 2015

Meta-analysis gives intravitreal ranibizumab vascular adverse risk profile

Intravitreal ranibizumab treatment for age-related macular degeneration does not elevate the risk of mortality, suggests a meta-analysis published in Ophthalmology.

13 Feb 2015

VEGF inhibition does not regulate collateral vessels in retinal vein occlusion

The formation of collateral vessels does not appear to improve visual acuity in patients with branch or central retinal vein occlusion, and is unaffected by anti-vascular endothelial growth factor therapy, a retrospective analysis suggests.

13 Feb 2015

Risk of ovarian cancer increased with even short-term HRT use

There has been much uncertainty regarding the risk of cancer associated with taking hormone replacement therapy (HRT) for the menopause. An analysis of all available evidence published in The Lancet today shows that HRT, even when taken for only a few years, significantly increases the risk of developing the two most common types of ovarian cancer.

13 Feb 2015

Biomedical use of gold nanotubes demonstrated in mouse model of human cancer

Scientists have shown that gold nanotubes have many applications in fighting cancer: internal nanoprobes for high-resolution imaging; drug delivery vehicles; and agents for destroying cancer cells.

13 Feb 2015

Lenvatinib trial offers hope for thyroid cancer patients

A new targeted therapy called lenvatinib has been shown to improve progression-free survival among patients with advanced thyroid cancer that is not responsive to iodine-131.

13 Feb 2015

Jazz Pharmaceuticals to present defibrotide results for hepatic VOD at BMT Tandem meetings

Jazz Pharmaceuticals plc announced today that researchers will present data on the use of defibrotide, an investigational medicine being studied in the United States (U.S.) for the treatment of hepatic veno-occlusive disease (VOD), a rare, potentially life-threatening, early complication in patients undergoing hematopoietic stem-cell transplantation (HSCT) therapy.

13 Feb 2015

Clinical trial proves ‘inside the artery’ therapy improves patient outcomes after stroke

"This clinical trial proves beyond any doubt that inside the artery therapy is the best possible treatment for patients suffering an acute ischemic stroke from a large artery occlusion," according to Donald Frei, MD, Neuro Interventional Surgeon at Swedish Medical Center and Radiology Imaging Associates in Englewood, CO.

13 Feb 2015

Astute Medical previews upcoming AKI & CRRT 2015 conference to be held in San Diego

Astute Medical, Inc., developer of the NephroCheck® Test, today previewed the upcoming AKI & CRRT 2015 conference to be held in San Diego from February 17 to February 20.

13 Feb 2015

Stem cell transplants more effective than mitoxantrone drug for people with severe multiple sclerosis

Stem cell transplants may be more effective than the drug mitoxantrone for people with severe cases of multiple sclerosis (MS), according to a new study published in the February 11, 2015, online issue of Neurology, the medical journal of the American Academy of Neurology.

12 Feb 2015

Longer donor leukocyte telomere length linked to improved survival following HCT

Among patients with severe aplastic anemia who received stem cell transplant from an unrelated donor, longer leukocyte (white blood cells) telomere length (a structure at the end of a chromosome) was associated with increased overall survival at 5 years, according to a study in the February 10 issue of JAMA.

12 Feb 2015

Researchers identify molecular pathways associated with distinct subsets of SSc patients

For years, doctors have been baffled about why some patients with systemic sclerosis (SSc) respond to therapy while others do not.

12 Feb 2015

$Lenvatinib therapy improves survival in patients with advanced radioiodine-refractory thyroid cancer$

Lenvatinib therapy improves survival in patients with advanced radioiodine-refractory thyroid cancer

In a pivotal Phase III study led by researchers at The University of Texas MD Anderson Cancer Center, the oral anti-angiogenic therapy lenvatinib has shown dramatic improvement in progression-free survival in patients with advanced radioiodine-refractory thyroid cancer.

12 Feb 2015

Therapy News and Research

R. Bryan Miller Symposium to spotlight special focus on rare disease research

Novartis receives priority review status from FDA for heart failure medicine LCZ696

Researchers identify two cell-signaling molecules that appear critical to stalling cancer's spread

Pelvalon receives FDA approval to market Eclipse System for improving bowel control in women

Eisai announces FDA approval of LENVIMA (lenvatinib) for treatment of RAI-refractory DTC

PAH survival unaffected by rheumatoid arthritis origin

Radionuclide angiography-assessed RVEF predicts PAH outcomes

Retinal venular calibre predicts ranibizumab vision improvement

Meta-analysis gives intravitreal ranibizumab vascular adverse risk profile

VEGF inhibition does not regulate collateral vessels in retinal vein occlusion

Risk of ovarian cancer increased with even short-term HRT use

Biomedical use of gold nanotubes demonstrated in mouse model of human cancer

Lenvatinib trial offers hope for thyroid cancer patients

Jazz Pharmaceuticals to present defibrotide results for hepatic VOD at BMT Tandem meetings

Clinical trial proves ‘inside the artery’ therapy improves patient outcomes after stroke

Astute Medical previews upcoming AKI & CRRT 2015 conference to be held in San Diego

Stem cell transplants more effective than mitoxantrone drug for people with severe multiple sclerosis

Longer donor leukocyte telomere length linked to improved survival following HCT

Researchers identify molecular pathways associated with distinct subsets of SSc patients

Lenvatinib therapy improves survival in patients with advanced radioiodine-refractory thyroid cancer

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Advancing Intracellular Delivery with LumiPore®

Latest News